tradingkey.logo

Bioxcel Receives Second Positive Recommendation To Continue Phase 3 Trial For Treatment Of Agitation Associated With Schizophrenia

ReutersJul 1, 2025 11:06 AM

- BioXcel Therapeutics Inc BTAI.O:

  • BIOXCEL THERAPEUTICS RECEIVES SECOND POSITIVE RECOMMENDATION FROM DATA SAFETY MONITORING BOARD (DSMB) TO CONTINUE SERENITY AT-HOME PIVOTAL PHASE 3 SAFETY TRIAL FOR ACUTE TREATMENT OF AGITATION ASSOCIATED WITH BIPOLAR DISORDERS OR SCHIZOPHRENIA

  • BIOXCEL THERAPEUTICS INC - TOPLINE DATA FOR SERENITY AT-HOME TRIAL EXPECTED IN Q3 2025

  • BIOXCEL THERAPEUTICS INC - DSMB RECOMMENDS CONTINUATION OF SERENITY AT-HOME TRIAL

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI